Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial
Nature Medicine · 2025
DOI: 10.1038/s41591-024-03428-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nature Medicine, 2025. Verfasst von Caroline Moreau und 26 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Dis…. Hauptthemen laut MEDLINE: Antiparkinson Agents, Dopamine, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: InBrain Pharma.
Abstract (Originalsprache)
Continuous compensation for cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. Dopamine does not cross the digestive and blood-brain barriers and is rapidly oxidized. The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the third ventricle, near the striatum. An open-label phase 1 study showed no serious adverse reactions induced by A-dopamine in 12 patients. A randomized, controlled, open-label, crossover phase 2 study of 1 month of A-dopamine versus 1 month of optimized oral antiparkinsonian therapy was conducted in 9 patients. The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedge g = -0.62 (95% confidence interval: -1.43, -0.08)). Home diaries were also significantly improved. These initial data on the feasibility, safety and effects of this new device-assisted therapy suggest validation by a large randomized double-blind trial. ClinicalTrials.gov registration: NCT04332276 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France.
- GRITA ULR 7365, University of Lille, Lille, France.
- Pharmacy CHU Lille, Lille, France.
- Department of Biostatistics, University of Lille, CHU de Lille, Lille, France.
- InBrain Pharma, Lille, France.
- Neurosurgery Department, University of Lille, CHU Lille, Lille, France.
Förderung
- InBrain Pharma
Zitieren
APA
Moreau, C., Odou, P., Labreuche, J., Demailly, A., Touzet, G., Reyns, N., Gouges, B., Duhamel, A., Barthelemy, C., Lannoy, D., Carta, N., Palas, B., Vasseur, M., Marchand, F., Ollivier, T., Leclercq, C., Potey, C., Ouk, T., Baigne, S., …, & Devos, D. (2025). Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03428-2
Vancouver
Moreau C, Odou P, Labreuche J, Demailly A, Touzet G, Reyns N, et al. Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03428-2
BibTeX
@article{Moreau2025,
author = {Moreau, Caroline and Odou, Pascal and Labreuche, Julien and Demailly, Alexandre and Touzet, Gustavo and Reyns, Nicolas and Gouges, Bastien and Duhamel, Alain and Barthelemy, Christine and Lannoy, Damien and Carta, Natacha and Palas, Benjamin and Vasseur, Michèle and Marchand, Felix and Ollivier, Thomas and Leclercq, Céline and Potey, Camille and Ouk, Thavarak and Baigne, Simon and Dujardin, Kathy and Carton, Louise and Rolland, Anne Sophie and Devedjian, Jean Christophe and Foutel, Véronique and Deplanque, Dominique and Fisichella, Matthieu and Devos, David},
title = {Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-024-03428-2}
}
EUVIMED